Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

High Expressions of Checkpoint Receptors in T Cells Subsets of Myelodysplastic Syndromes Patients with TP53 Mutations

Lingxu Jiang, Xin Huang, Xinping Zhou, Li Ye, Lu Wang, Chen Mei, Liya Ma, Gaixiang Xu, Chao Hu, Ziyang Zhou, Xiaozhen Liu, Yueyuan Han, Zheng Ge, Hongyan Tong

Blood (2023) 142 (Supplement 1): 4614.

https://doi.org/10.1182/blood-2023-182601

Published: 2023

Journal Articles

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of the EB Subtype of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

Gaixiang Xu, Wei Wang, Shuanghong Zhu, Kongfei Li, Xinping Zhou, Liya Ma, Li Ye, Chen Mei, Lu Wang, Lingxu Jiang, Haitao Meng, Wen-Juan Yu, Jie Jin, Hongyan Tong, Jian Huang

Blood (2023) 142 (Supplement 1): 6481.

https://doi.org/10.1182/blood-2023-184789

Published: 2023

Journal Articles

Recombinant Human Erythropoietin Combined with All-Trans Retinoic Acid and Testosterone Undecanoate in the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes: Updated Results of a Multicenter, Single-Arm, Prospective Trial

Chen Mei, Yaping Xie, Yanping Shao, Zheng Ge, Hongyan Tong

Blood (2023) 142 (Supplement 1): 6484.

https://doi.org/10.1182/blood-2023-186427

Published: 2023

Journal Articles

Recombinant Human Erythropoietin Combined with All-Trans Retinoic Acid and Testosterone Undecanoate in the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes: A Multicenter, Open-Label, Prospective Trial

Chen Mei, Yaping Xie, Yanping Shao, Jie Jin, Hongyan Tong

Blood (2022) 140 (Supplement 1): 9776.

https://doi.org/10.1182/blood-2022-169145

Published: 2022

Journal Articles

EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes

Qi Zhang, Wei Lang, Lu Wang, Wenli Yang, Yingwan Luo, Shuanghong Zhu, Lingxu Jiang, Yuxia Wang, Chen Mei, Xinping Zhou, Yanling Ren, Liya Ma, Li Ye, Xingnong Ye, Gaixiang Xu, Jie Sun, Jie Jin, Hongyan Tong

Blood (2022) 140 (Supplement 1): 9767–9768.

https://doi.org/10.1182/blood-2022-165886

Published: 2022

Journal Articles

The Transcriptional Factor ONECUT3 Is a Driver and Therapeutic Target for Complex Karyotype MDS

Yingwan Luo, Xiaomin Feng, Wei Lang, Chen Mei, Rongzhen Xu, Gang Huang, Hongyan Tong

Blood (2022) 140 (Supplement 1): 4018–4019.

https://doi.org/10.1182/blood-2022-166618

Published: 2022

Journal Articles

The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway

Lingxu Jiang, Xinping Zhou, Chao Hu, Chen Mei, Gaixiang Xu, Liya Ma, Yanling Ren, Li Ye, Lu Wang, Yingwan Luo, Jie Jin, Jie Sun, Hongyan Tong

Blood (2022) 140 (Supplement 1): 6894–6895.

https://doi.org/10.1182/blood-2022-165203

Published: 2022

Journal Articles

Co-Mutation Landscape and Clinical Significance of RAS Pathway Related Gene Mutations in Patients with Myelodysplastic Syndrome

Yanling Ren, Wei Lang, Chen Mei, Yingwan Luo, Jie Jin, Hongyan Tong

Blood (2022) 140 (Supplement 1): 12305.

https://doi.org/10.1182/blood-2022-169177

Published: 2022

Journal Articles

RIPK3 Deficiency Caused By DNA Hypermethylation Blocks R-2-Hydroxyglutarate Induced Necroptosis in AML with IDH Mutation

Shuanghong Zhu, Chen Mei, Yuxia Wang, Jie Jin, Jie Sun, Hongyan Tong

Blood (2022) 140 (Supplement 1): 8715–8716.

https://doi.org/10.1182/blood-2022-168309

Published: 2022

Journal Articles

15-Days Duration of Venetoclax Combined with Azacitidine in the Treatment of Relapsed/Refractory High-Risk Myelodysplastic Syndromes: A Retrospective Single-Center Study

Hongyan Tong, Chen Mei, Yanling Ren, Xinping Zhou, Yingwan Luo, Jie Jin

Blood (2022) 140 (Supplement 1): 12351–12352.

https://doi.org/10.1182/blood-2022-168938

Published: 2022

Journal Articles

R-2HG/KDM2B/RIPK1 Signaling Mediates Necroptosis in Myelodysplastic Syndromes

Shuanghong Zhu, Chen Mei, Hongyan Tong, Jie Jin, PhD

Blood (2019) 134 (Supplement_1): 5049.

https://doi.org/10.1182/blood-2019-125482

Published: 2019

Journal Articles

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

Hongyan Tong, Docter, Xinping Zhou, Chen Mei, Jin Zhang, Ying Lu, Jianping Lan, MD, Shengyun Lin, Yuefeng Zhuang, Yuemin Kuang, Yanling Ren, Liya Ma, Juying Wei, Li Ye, Weilai Xu, Kongfei Li, Chenxi Lu, Jie Jin, MD PhD

Blood (2019) 134 (Supplement_1): 2594.

https://doi.org/10.1182/blood-2019-127675

Published: 2019

Journal Articles

The High NRF2 Expression Confers Chemotherapy Resistance through Upregulated DUSP1 in Myelodysplastic Syndromes

Peipei Lin, Yanling Ren, Xinping Zhou, Chen Mei, Chao Hu, Yingwan Luo, Yile Zhou, Xiaomei Yan, Gang Huang, PhD, Hongyan Tong, PhD

Blood (2017) 130 (Supplement 1): 2956.

https://doi.org/10.1182/blood.V130.Suppl_1.2956.2956

Published: 2017

Journal Articles

Synergistic Effect of Sequential Combination of Decitabine and Idarubicin in Mouse Model of Human Acute Myeloid Leukemia

Hongyan Tong, MD, Kongfei Li, Chen Mei, Chao Hu, Jie Jin, MD

Blood (2012) 120 (21): 1515.

https://doi.org/10.1182/blood.V120.21.1515.1515

Published: 2012

Journal Articles

p53-Independent Anti-Myeloma Activity of Prima-1 met

Manujendra N Saha, Hua Jiang, Chen Mei-Hsi, Hong Chang

Blood (2011) 118 (21): 1826.

https://doi.org/10.1182/blood.V118.21.1826.1826

Published: 2011

Journal Articles

Methylation Analysis of the Wnt Antagonist in Myelodysplastic Syndrome

Hongyan Tong, MD, Chen Mei, Kongfei Li, Jie Jin, MD

Blood (2011) 118 (21): 5048.

https://doi.org/10.1182/blood.V118.21.5048.5048

Published: 2011

Journal Articles

Synergistic Depression of Wnt Pathway by Sequential Combination of Decitabine and Idarubicin in Human Myeloid Leukemic Cell Lines,

Hongyan Tong, MD, Kongfei Li, Chen Mei, Jie Jin, MD

Blood (2011) 118 (21): 3628.

https://doi.org/10.1182/blood.V118.21.3628.3628

Published: 2011

Journal Articles

Expression of the Hypoxia-Inducible Factors In the AML and MDS: Is Not Associated with the Von Hippel-Lindau Gene

Hongyan Tong, Chen Mei, Kongfei Li, Jie Jin

Blood (2010) 116 (21): 5114.

https://doi.org/10.1182/blood.V116.21.5114.5114

Published: 2010

NARROW

High Expressions of Checkpoint Receptors in T Cells Subsets of Myelodysplastic Syndromes Patients with TP53 Mutations

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of the EB Subtype of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

Recombinant Human Erythropoietin Combined with All-Trans Retinoic Acid and Testosterone Undecanoate in the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes: Updated Results of a Multicenter, Single-Arm, Prospective Trial

Recombinant Human Erythropoietin Combined with All-Trans Retinoic Acid and Testosterone Undecanoate in the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes: A Multicenter, Open-Label, Prospective Trial

EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes

The Transcriptional Factor ONECUT3 Is a Driver and Therapeutic Target for Complex Karyotype MDS

The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway

Co-Mutation Landscape and Clinical Significance of RAS Pathway Related Gene Mutations in Patients with Myelodysplastic Syndrome

RIPK3 Deficiency Caused By DNA Hypermethylation Blocks R-2-Hydroxyglutarate Induced Necroptosis in AML with IDH Mutation

15-Days Duration of Venetoclax Combined with Azacitidine in the Treatment of Relapsed/Refractory High-Risk Myelodysplastic Syndromes: A Retrospective Single-Center Study

R-2HG/KDM2B/RIPK1 Signaling Mediates Necroptosis in Myelodysplastic Syndromes

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

The High NRF2 Expression Confers Chemotherapy Resistance through Upregulated DUSP1 in Myelodysplastic Syndromes

Synergistic Effect of Sequential Combination of Decitabine and Idarubicin in Mouse Model of Human Acute Myeloid Leukemia

p53-Independent Anti-Myeloma Activity of Prima-1 met

Methylation Analysis of the Wnt Antagonist in Myelodysplastic Syndrome

Synergistic Depression of Wnt Pathway by Sequential Combination of Decitabine and Idarubicin in Human Myeloid Leukemic Cell Lines,

Expression of the Hypoxia-Inducible Factors In the AML and MDS: Is Not Associated with the Von Hippel-Lindau Gene

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only